Recognizing neuroleptic malignant syndrome [1]

CMAJ. Canadian Medical Association Journal

Volumn 170, Issue 11, 2004, Pages 1645-

  Rosebush, Patricia I ^a   Garside, Sarah ^a   Mazurek, Michael F ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DOPAMINE 2 RECEPTOR BLOCKING AGENT;

AGED; AUTONOMIC DYSFUNCTION; CASE REPORT; CLINICAL FEATURE; FEVER; HUMAN; LETTER; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; TREMOR;

EID: 2942580714     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1031692     Document Type: Letter

References (5)

1. Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ 2003;169(5):439-42.
2. Rosebush PI, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome in 15 patients. Am J Psychiatry 1989;146:717-25.
3. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 1989;50:295-8.
4. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome: Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 1991;159:709-12.
5. Rosebush PI, Mazurek MF. Bromocriptine and neuroleptic malignant syndrome [letter]. J Clin Psychiatry 1991;52:41-2.